Exosome-based Detection of Molecular Residual Disease in Stage II-III Colorectal Cancer

Completed

Conditions studied: Colo-rectal Cancer, Colorectal Cancer Recurrent

In brief

This study aims to establish an exosome-based liquid biopsy signature to detect molecular residual disease (MRD) in stage II-III colorectal cancer (CRC) patients. Identifying patients with MRD after surgery is crucial for selecting appropriate candidates for adjuvant chemotherapy (ACT), allowing for more personalized treatment approaches and potentially improving patient outcomes.

Key facts

Study ID

NCT06654622

Run by

City of Hope Medical Center

People needed

175

Starts

2023-04-01

Expected to finish

2026-02-18

Last updated by the study team

2026-03-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with pathologically confirmed stage II or III colorectal cancer.
• Patients who have undergone curative-intent surgery.
• Patients with no evidence of distant metastasis (stage IV).
• Patients aged 18 years or older.
• Patients who provided written informed consent.

You may not qualify if…

• Patients with stage IV cancer or those receiving neoadjuvant therapy.
• Patients with non-curative resection or requiring urgent surgery.
• Patients with a follow-up period of fewer than 3 years.
• Patients with severe comorbidities or who are unable to participate in follow-up assessments.

Where it is running

• City of Hope Medical Center — Duarte, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.